MedTrace Logo

Network-based biOmarker Discovery of Neurodegenerative Diseases Using Multimodal Connectivity

NCT06080659 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-01-05

No results posted yet for this study

Summary

The aim of the NODAL clinical trial is to demonstrate the feasibility of new, low-cost, non-invasive biomarkers of neurodegenerative pathologies as early Alzheimer and Parkinson, based on the estimation of the multimodal connectome.

Conditions

  • Alzheimer Disease, Early Onset
  • Parkinson Disease

Interventions

DIAGNOSTIC_TEST

fMRI

functional MRI

DIAGNOSTIC_TEST

CONFMEM

The aim of this paradigm is to identify the impact of cognitive conflict situations on recognition memory (the ability to judge whether or not a stimulus has been previously presented).

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Pierre-Yves JONIN, PhD · CHU Rennes

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-06
Primary Completion
2026-11-30
Completion
2026-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06080659 on ClinicalTrials.gov